12/14/2020 7:06:14 AM
Iovance Biotherapeutics Appoints Jean-Marc Bellemin As CFO
1/15/2020 8:20:46 AM
Iovance Completes Patient Dosing In Registration-Enabling Cohort 4 Of C-144-01 Melanoma Study With Lifileucel
1/12/2020 8:07:27 PM
Iovance And Cellectis Enter Into Research Collaboration And Exclusive Worldwide License Deal
1/12/2020 8:05:00 PM
Iovance Biotherapeutics Obtains License To Develop And Commercialize Novel IL-2 Analog
10/2/2019 7:09:12 AM
Iovance Biotherapeutics Announces Four Abstracts Highlighting TIL Therapy To Be Presented At 2019 SITC Annual Meeting
7/18/2019 8:05:10 AM
Iovance Biotherapeutics Appoints Friedrich Graf Finckenstein As Chief Medical Officer
6/11/2019 7:11:20 AM
Iovance Biotherapeutics Appoints Athena Countouriotis To Board
4/3/2019 7:09:24 AM
Iovance Biotherapeutics To Present New Data From Ongoing Studies Of TIL Therapy At 2019 ASCO Meeting
2/26/2019 7:29:00 AM
Iovance Biotherapeutics: FDA Grants Fast Track Designation For LN-145 For Cervical Cancer